Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium

The Lancet Oncology 2026

View at publisher
Authors: Joachim Widder, Guus M. Bol, Inga-Malin Simek, Felix Ehret, Hoda Abdel-Aty, Selma Basic, David Chuter, Jacqueline Daly, Patricia Fairbrother, Donjeta Zeqa, Frank Aboubakar Nana, Vérane Achard
+26 more Stefanie Corradini, Dora Correia, Dirk De Ruysscher, Anne-Marie C Dingemans, Corinne Faivre-Finn, Silke Gillessen, Marianne G. Guren, Lizza Hendriks, Wolfgang G Kunz, Frederic E Lecouvet, Antonin Levy, Yolande Lievens, Fiona McDonald, Icro Meattini, Felix Oppong, Daniela Oprea-Lager, David Palma, Gitte Fredberg Persson, Jordi Remon, Miet Vandemaele, Hanneke W M van Laarhoven, Helena M Verkooijen, Luca Visani, Thomas Zilli, Piet Ost, Matthias Guckenberger
DOI: 10.1016/s1470-2045(26)00075-6
Cited by: 5
References: 34

Fields of Study & Subjects

Lung Cancer Research Studies Lung Cancer Treatments and Mutations Cancer Research and Treatments

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
5
Pages
e238–e247
Publication date
27 April 2026
Language
EN